Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

101 to 125 of 237 results

FDA accepts The Medicines Company's NDA for oritavancin with priority review

FDA accepts The Medicines Company's NDA for oritavancin with priority review

19-02-2014

The US Food and Drug Administration has accepted the filing of The Medicines Company’s New Drug Application…

Antibiotics and Infectious diseasesNorth AmericaoritavancinPharmaceuticalRegulationThe Medicines CompanyUSA

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Infectex acquires exclusive rights to Qurient's TB drug Q203

13-02-2014

Russian and Korean biotech companies Infectex and Qurient have entered a license agreement granting Infectex…

Antibiotics and Infectious diseasesEastern EuropeInfectexLicensingPharmaceuticalQ203QurientRussia

Joint European program targets novel antibiotic

12-02-2014

More than 30 European universities and companies, led by GlaxoSmithKline and Uppsala University, are…

Antibiotics and Infectious diseasesEuropeMerck & CoPharmaceuticalResearch

Debiopharm to acquire Affinium's antibiotic clinical assets and platform

11-02-2014

Swiss drug developer Debiopharm Group has entered into an agreement to acquire Canadian venture capital…

Affinium PharmaceuticalsAFN-1720Antibiotics and Infectious diseasesDebiopharmMergers & AcquisitionsPharmaceutical

AbbVie’s hepatitis C Phase III trials all record top results

AbbVie’s hepatitis C Phase III trials all record top results

04-02-2014

US drugmaker AbbVie has announced the completion of its Phase III clinical program and released results…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research

28-01-2014

Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

TaiGen Biotech signs up deal for Taigexyn in Russia and other states

15-01-2014

Taiwan-based drug developer TaiGen Biotechnology has signed an exclusive agreement with R-Pharm, a leading…

Antibiotics and Infectious diseasesEastern EuropeLicensingnemonoxacinPharmaceuticalR-PharmRussiaTaiGen BiotechTaigexynTurkey

Sanofi and Fraunhofer-Gesellschaft aim to create new antibiotics to fight infectious diseases

Sanofi and Fraunhofer-Gesellschaft aim to create new antibiotics to fight infectious diseases

15-01-2014

French drug major Sanofi (Euronext: SAN) and the European research organization Fraunhofer-Gesellschaft…

Antibiotics and Infectious diseasesFrancePharmaceuticalResearchSanofi

HedgePath Pharma to repurpose antifungal drug as cancer inhibitor

09-01-2014

USA-based clinical stage biopharma company HedgePath Pharmaceuticals has announced plans to repurpose…

Antibiotics and Infectious diseasesHedgePath PharmaceuticalsitraconazoleMayne PharmaOncologyPharmaceuticalResearchSUBA-Itraconazole

Clinigen to provide first access to anti-bacterial Vibativ in Europe

Clinigen to provide first access to anti-bacterial Vibativ in Europe

08-01-2014

UK-based Clinigen Group has announced the initiation of an early access program to provide the anti-bacterial…

Antibiotics and Infectious diseasesClinigen GroupEuropeLicensingPharmaceuticalProductionUKVibativ

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

06-01-2014

Japanese drug major Astellas Pharma has entered into a strategic partnership with ClearPath Development…

Antibiotics and Infectious diseasesAstellas PharmaClearPath DevelopmentLicensingMergers & AcquisitionsMymetics CorpOtsukaPharmaceuticalRSV CorpTaiho Pharmaceutical

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted

03-01-2014

China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

Cubist’s tedizolid NDA accepted for priority review in USA

Cubist’s tedizolid NDA accepted for priority review in USA

31-12-2013

The US Food and Drug Administration has accepted Cubist Pharmaceuticals’ New Drug Application for its…

Antibiotics and Infectious diseasesBayerCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationtedizolidTrius TherapeuticsUSA

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products

23-12-2013

Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP

22-12-2013

Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

17-12-2013

US drugmaker Cubist Pharmaceuticals saw its shares jump 8.3% to $68 in premarket trading yesterday, when…

Antibiotics and Infectious diseasesceftolozoneCubist PharmaceuticalsEuropeNorth AmericaPharmaceuticalRegulationResearchtazobactam

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

GSK’s Synflorix gets additional indication in Europe

GSK’s Synflorix gets additional indication in Europe

05-12-2013

The European Commission has granted marketing authorization for an additional indication for UK pharma…

Antibiotics and Infectious diseasesEuropeGlaxoSmithKlinePharmaceuticalRegulationSynflorix

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

The Medicines Company acquires antibiotics maker Rempex Pharma

04-12-2013

USA-based The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential…

Antibiotics and Infectious diseasesMergers & AcquisitionsPharmaceuticalRempex PharmaceuticalsThe Medicines Company

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

04-12-2013

Ahead of the Global Fund replenishment conference in Washington DC this week, international medical humanitarian…

Anti-viralsAntibiotics and Infectious diseasesGlobalPharmaceutical

MRCF invests in Australian antibiotics start-up Auspherix

03-12-2013

Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

101 to 125 of 237 results

COMPANY SPOTLIGHT

Menarini

Back to top